Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of an mRNA-based seasonal influenza vaccine in adults aged 18-64 years
2026-526925-17-00Phase 3Authorised
- Sponsor
- GSK
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, single-blind trial of GSK4382276A, influenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (propiolactone inactivated) and Alpharix in influenza (2 arms), sponsored by GSK. Primary endpoints: Immunogenicity at Day 29 and Safety and reactogenicity. Planned start Oct 2026; status: authorised.
02
Drugs
GSK4382276Ainfluenza a virus a/singapore/infimh-16-0019/2016 ivr-186 (h3n2) antigen (propiolactone inactivated)Alpharix
03
Conditions
influenza
Beyond the preview
Go deeper on 2026-526925-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526925-17-00.